Search

Your search keyword '"Ponce, Santiago"' showing total 318 results

Search Constraints

Start Over You searched for: Author "Ponce, Santiago" Remove constraint Author: "Ponce, Santiago"
318 results on '"Ponce, Santiago"'

Search Results

1. Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review

2. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

3. Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

4. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

5. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

6. Impact of Clonal Hematopoiesis–Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial

7. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer

8. Effects of Virtual Education on Lateral Mastery, Auditory Sequential Memory and Rhythm During the Literacy Process

9. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

11. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors

12. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

13. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

14. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

16. Abstract B083: The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials

18. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

19. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)

22. Supplementary Data S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

23. Supplementary Figure S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

24. Association between Lung Immune Prognostic Index and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer

25. Supplementary Methods S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

26. Supplementary Table S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

32. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

33. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

34. Data from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

35. Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

36. Space Murder Mystery

38. Abstract 4526: Molecular landscape of clonal hematopoiesis in patients with lung cancer: First results of the CHIC study

40. Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions

42. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

43. Meniscus Tears

44. Distal Femoral Fractures

45. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

46. Gabriela Mistral y su praxis educativa sociohistórica.

Catalog

Books, media, physical & digital resources